Advertisement

Topics

Troponin trumps CK-MB—time to stop double-ordering

12:01 EDT 8 Sep 2017 | Cardiovascular Business

Innovation in medicine is amazing, adding tests, devices, drugs and procedures to our arsenal all the time. We’re good at adding new options that are better, stronger and faster but often remiss in sunsetting old options. And it’s costing us millions each year in diagnosing acute MI patients as a recent JAMA Internal Medicine article points out.

Original Article: Troponin trumps CK-MB—time to stop double-ordering

NEXT ARTICLE

More From BioPortfolio on "Troponin trumps CK-MB—time to stop double-ordering"

Quick Search
Advertisement